MedTrace Logo

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

NCT02617134 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-12-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Conditions

  • Malignant Glioma of Brain
  • Colorectal Carcinoma
  • Gastric Carcinoma

Interventions

BIOLOGICAL

anti-MUC1 CAR-T cells

Sponsors & Collaborators

  • The First People's Hospital of Hefei

    collaborator OTHER

  • Hefei Binhu Hospital

    collaborator OTHER

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lin Yang, Ph.D. · PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-30
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02617134 on ClinicalTrials.gov